Drug discovery

#Biotechnology #Drug development #Drug discovery #Narrated podcasts #Pharmaceutical

Evolving Models for NASH Drug Discovery: Tools for stemming a silent epidemic

Non-alcoholic fatty liver disease (NAFLD) has quietly become one of the most common causes of chronic liver disease in the modern world. If this prevalence is allowed to continue the economic and clinical burden will reach a staggering level. Non-alcoholic fatty liver disease (NAFLD) consists of a complex combination of… Read More

#Podcasts

#Drug discovery

Collaboration aims to accelerate drug discovery in mental health care

COMPASS Pathways joins the Psychiatry Consortium in a collaboration to accelerate drug discovery in mental health care COMPASS Pathways (CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has joined the Psychiatry Consortium, an international collaboration to accelerate drug discovery and development… Read More

#News

#Biotechnology #Drug discovery #Drug targets #Hit identification #Immunotherapy #Oncology

Partnership will progress targeted cancer immune therapy drug discovery

APEIRON Biologics, a biotech company developing breakthrough therapies to treat cancer and respiratory conditions, has selected Domainex to provide integrated lead optimisation services in order to advance the development of inhibitors for the E3 ubiquitin ligase Cbl-b through small molecule drug discovery. Under the terms of the agreement, Domainex, an… Read More

#Cancer Research #News

#Assay development & optimisation #Drug discovery

Putting the dynamics into compound profiling: using kinetic assays to shape early stage drug discovery

In vitro early stage compound profiling often focusses on single timepoint measurements of drug action, for example the affinity of the drug for its target at equilibrium, or the endpoint response in a signalling assay. However, in vivo, drug action occurs within a highly dynamic system. Drug and competing messenger… Read More

Webinar date:
Brought to you by SPT Labtech
#Webinars

#Biopharma #Drug development #Drug discovery

Thermo Fisher Scientific extends collaboration to advance biopharma discovery

Thermo Fisher Scientific and Symphogen, an affiliate of and the antibody centre of excellence within the international pharmaceutical company, Servier, have extended a collaboration to deliver innovative characterisation and quality control workflows for the simplified analysis of complex therapeutic proteins to advance biopharmaceutical discovery and development. Since the collaboration was… Read More

#News

#Autoimmune disease #Drug candidates #Drug discovery

Beetroot peptide potential drug candidate for neurodegenerative and inflammatory diseases

In a recent study, a research group led by Christian Gruber at MedUni Vienna’s Institute of Pharmacology isolated a peptide (small protein molecule) from beetroot. The peptide is able to inhibit a particular enzyme that is responsible for the breakdown of messenger molecules in the body. Due to its particularly… Read More

#Editor's Choice #News

#Assay development optimisation & technology #Drug discovery #High Content Screening #RNA

PerkinElmer to acquire Horizon Discovery for $383 million

PerkinElmer will acquire Horizon Discovery for approximately $383 million (£296 million). The transaction is expected to close in the first quarter of 2021 subject to conditions. The investment will allow PerkinElmer to expand its portfolio of leading, automated life sciences discovery and applied genomics solutions to include gene editing and… Read More

#News #Trending News

#Drug discovery #Novel candidates

Tube-dwelling anemone toxins have pharmacological potential

By André Julião, Agência FAPESP Researchers based in Brazil and the US have completed the first-ever mapping exercise to profile the toxins produced by tube-dwelling anemones, or cerianthids, a family of marine animals belonging to the same phylum (Cnidaria) as sea anemones, jellyfish and corals. The analysis revealed that the… Read More

#Editor's Choice #News

#Drug development #Drug discovery #Oncology

New drug for difficult-to-drug cancer mutation could be key treatment for other cancers

A new drug designed to counter the effects of an important, but very hard to target, cancer mutation could be effective against a range of tumour types including lung and gynaecological cancers, a new clinical trial shows. Researchers used an innovative, intermittent treatment schedule to limit the drug’s toxicity, and… Read More

#Cancer Research #News #Trending News

#Biotechnology #Drug development #Drug discovery #Life sciences #Narrated podcasts #Pharmaceutical

Reducing the PAINS in High Throughput Screening: Assay design as a tool for maximising efficiency

This article will describe, with examples, how understanding the likely mechanisms of false positives in advance of screening informs the design of the hit triage, thus increasing the likelihood of discovering optimisable chemical matter and avoiding costly wasting of resource. We describe the use of a bespoke ‘Robustness Set’ of… Read More

#Podcasts

#Bioproduction #Drug discovery

Testa Challenge 2020 attracts bioprocessing innovators

Six bioprocessing innovators have successfully completed the inaugural Testa Challenge 2020. Held over an intensive week in the Testa Center located at Cytiva´s Uppsala site, a biomanufacturing scale-up facility, the Testa Challenge aims to allow start-ups, research groups and companies from around the world to run and validate their innovative… Read More

#News

#Drug candidates #Drug discovery

BioIVT kit aids liver toxicity and inflammation studies for drug discovery research

BioIVT has launched the HEPATOMUNE kit, a long-term, stable, in vitro model for evaluating immune-related and inflammation-mediated liver injury. Hepatomune cultures are composed of hepatocytes, stromal cells and Kupffer cells in a tri-culture, mimicking the physiological microenvironment of the liver, and providing an optimal model for studying cytokines and cytokine… Read More

#News

#Drug discovery #Screening

CU Anschutz announces technology to cut drug screening time in half

Author Julia Milzer, CU Anschutz  The CU Skaggs School of Pharmacy and Pharmaceutical Sciences at CU Anschutz has announced a new drug discovery technology that can cut the screening time for new drug therapies by half. It will enable rapid and cost-effective screening of hundreds of thousands of potential therapies… Read More

#News